BirchBioMed announced that the FDA has granted orphan drug designation (ODD) to FS2 (kynurenic acid) for the investigational treatment of idiopathic pulmonary fibrosis (IPF).
"Being granted Orphan Drug Designation by the FDA is a pivotal milestone in BirchBioMed's development of FS2 for the treatment of IPF, a debilitating and fatal disease that has no more than a 5-year life expectancy after diagnosis," said Mark S. Miller, Chairman and CEO of BirchBioMed, "The FDA's designation provides BirchBioMed with development and commercial capabilities to address this high, unmet medical need."
The FDA's ODD program is designed to incentivize and facilitate the development of investigational drugs / compounds intended for the safe and effective treatment, diagnosis, or prevention of rare diseases or disorders such as IPF, that affect fewer than 200,000 people in the U.S. Idiopathic pulmonary fibrosis (IPF), a rare and serious chronic lung disease, results in scarring (fibrosis) of the lungs for an unknown reason. It is characterized by the thickening and stiffening of lung tissue surrounding the air sacs, or alveoli, in the lungs. Over time, these changes can cause permanent scarring in the lungs, making it progressively more difficult to breathe. There is currently no cure for IPF, which affects between 3 million to 5 million people worldwide.
Carlos Camozzi, Chief Medical Officer, BirchBioMed, said: "This ODD indicates the scientific value of FS2 in the investigational treatment of IPF and underscores the opportunity for IPF patients to participate in our clinical trials. BirchBioMed is seeking regulatory approval to begin clinical trials on the systemic use of FS2 for the treatment of organ fibrosis, beginning with IPF early next year. As experts in the development of products for scarring and other fibrosis-related disorders, we are laser focused on FS2's potential to transform the lives of people suffering from this severe, chronic, deteriorating, irreversible, life-threatening lung disease."
About FS2
FS2 (kynurenic acid) was first identified as a potential drug candidate for clinical research by investigators at the University of British Columbia for the topical treatment of scars and for systemic treatment of organ fibrosis, including scarring in the lungs, liver, kidneys, and heart. In preclinical trials, FS2 demonstrated the prevention of scars as well as the breakdown and reduction of existing scars that occurred after injury, surgery, or disease, both externally and internally. A subsequent Phase II randomized double-blind clinical trial comparing the safety and efficacy of topical FS2 cream demonstrated superior, statistically significant efficacy on mature keloid scars as compared not only to the vehicle control but to a market leading scar cream. FS2 is unique in its therapeutic category as it targets scarring on the molecular level.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!